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Abstract
Mast cells (MCs) are heterogeneous cells whose phenotype is modulated by signals received from the local
microenvironment. Recent studies have identified the mesenchymal-derived cytokine IL-33 as a potent direct activator of
MCs, as well as regulator of their effector phenotype, and have implicated this activity in the ability of mast cells to
contribute to murine experimental arthritis. We explored the hypothesis that IL-33 enables participation of synovial MCs in
murine K/BxN arthritis by promoting their activation by IgG immune complexes. Compared to wild-type (WT) control mice,
transgenic animals lacking the IL-33 receptor ST2 exhibited impaired MC-dependent immune complex-induced vascular
permeability (flare) and attenuated K/BxN arthritis. Whereas participation of MCs in this model is mediated by the activating
IgG receptor FccRIII, we pre-incubated bone marrow-derived MCs with IL-33 and found not only direct induction of cytokine
release but also a marked increase in FccRIII-driven production of critical arthritogenic mediators including IL-1b and CXCL2.
This ‘‘priming’’ effect was associated with mRNA accumulation rather than altered expression of Fcc receptors, could be
mimicked by co-culture of WT but not ST2
2/2 MCs with synovial fibroblasts, and was blocked by antibodies against IL-33. In
turn, WT but not ST2
2/2 MCs augmented fibroblast expression of IL-33, forming a positive feedback circuit. Together, these
findings confirm a novel role for IL-33 as an amplifier of IgG immune complex-mediated inflammation and identify
a potential MC-fibroblast amplification loop dependent on IL-33 and ST2.
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Introduction
Mast cells (MCs) are hematopoietic cells that develop from
circulating progenitors and differentiate into fully granulated
effector cells within the local tissue milieu. The survival,
development, phenotype, and function of these immune cells
are modulated by contact-dependent and -independent signals
from the microenvironment [1,2,3,4]. In many locations, MCs
reside in close proximity to fibroblasts, and prior work has
demonstrated the existence of intricate physical contacts
between the two cell types [5,6,7]. This interaction is of critical
importance to MCs, since expression of membrane-bound Kit
ligand (KitL) by fibroblasts enables the survival of MCs in
tissues [8,9]. Fibroblasts also modulate the effector phenotype of
MCs, including their expression of eicosanoids and granule
proteases [5,6]. In turn, MCs influence the growth and
activation of fibroblasts [10,11].
Among the multiple factors known to influence MC phenotype
and behavior, recent interest has focused on IL-33, a pro-
inflammatory member of the IL-1 cytokine family [12,13]. IL-33 is
produced primarily by fibroblasts, smooth muscle cells, keratino-
cytes, and endothelial cells; MCs themselves have also been
identified as a potential source [14,15]. Acting via its receptor
ST2, IL-33 triggers MCs to release numerous cytokines and
chemokines [16,17,18,19,20,21,22], an activity implicated in the
pathogenesis of anaphylaxis and in the role of mast cells as sensors
of tissue injury [22,23]. Moreover, exposure of MCs to IL-33
augments expression of cytokines in MCs activated concomitantly
via the high-affinity IgE receptor FceRI [24,25]. IL-33 is also the
first factor shown to promote the accumulation in granules of
mouse MC protease 6 [26], an ortholog of human tryptase b that
plays a role in innate immunity and inflammatory arthritis
[27,28,29]. Thus, IL-33 also is a granule maturation factor for
MCs.
Recent studies have implicated IL-33 in the activation of
synovial MCs in murine arthritis [21,30,31]. Transgenic mice
lacking ST2 exhibit impaired degranulation of synovial MCs,
while MCs cultured overnight in the presence of arthritogenic K/
BxN mouse serum have been reported to become susceptible to
IL-33-induced degranulation [31]. However, MC-dependent
vasogenic edema begins within minutes of the administration of
K/BxN mouse serum, a time course that may be too rapid for de
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47252novo release of IL-33 [14,32,33,34]. Further, genetic studies have
demonstrated that FccRIII is an obligate pathway for the
activation of synovial MCs in K/BxN arthritis [33,35]. It therefore
remains unclear, in the context of arthritis, whether the major role
of IL-33 is to activate MCs directly or rather to potentiate their
activation via other pathways, such as Fc receptors. To address
this question, we tested the role of IL-33 in the response of MCs to
FccRIII ligation, and explored the role of this cytokine in the
interactions between MCs and synovial fibroblasts, a potential
source of IL-33 within the joint.
Materials and Methods
Reagents
The Mouse Cytokine Array Panel A, recombinant mouse IL-
33, and specific ELISAs for CXCL2, tumor necrosis factor-
a (TNF-a), IL-1b, IL-6, IL-33 and anti-IL-33 Ab (MAB3626)
were obtained from R&D Systems (Minneapolis, MN). Mouse
IgG1 isotype antibody was from Biolegend (San Diego, CA).
Anti-IL-33 (Nessy-1) was from Enzo Life Sciences (Farmingdale,
NY). Recombinant mouse IL-3 and KitL were obtained from
Peprotech (Rocky Hill, NJ), and endotoxin-free rat anti-mouse
FccRII/III antibody (Ab) (clone 2.4G2) was obtained from
BioXCell (West Lebanon, NH). Additional reagents included
2.4G2-PE Ab (BD Biosciences, San Diego, CA) and rat anti-
FccRIII Abs (clone 275003, unconjugated and carboxyfluor-
escein conjugated, R&D Systems).
Mice
Wild-type (WT) C57BL/6J (B6) and B6;129S4-Fccr2b
tm1Ttk/J
(FccRII
2/2) mice were from the Jackson Labs (Bar Harbor, ME).
ST2
2/2 B6 mice were obtained from Dr. Andrew McKenzie
(MRC Laboratory of Molecular Biology) [36]. Animal experi-
ments were approved by the Institutional Animal Care and Use
Committee of the Dana Farber Cancer Institute (Animal Welfare
Assurance Number: A3023-01). All efforts were made to minimize
the suffering of animals used in this research.
Experimental Arthritis
Pro-arthritic serum was isolated from K/BxN mice as pre-
viously described [37]. K/BxN arthritis was induced by the
intraperitoneal injection of diluted K/BxN serum (75 ml serum
with 75 ml endotoxin-free PBS) on days 0 and 2 of each
experiment. Arthritis was graded using a 0–12 clinical scale (0–3
per paw) as well as by caliper measurement of ankle thickness, as
described [37]. ‘‘Flare’’ (acute paw swelling) was measured by
caliper in all 4 paws 30 minutes after the first serum administration
[33]. Histological assessment was performed on paraffin-embed-
ded 4-mm sections stained with hematoxylin and eosin, and
synovial inflammation, cartilage injury, and bone erosion were
graded in blinded fashion on a 0–5 scale using an established
system [35].
Cell Culture and Mast Cell Activation
Mouse bone marrow derived MCs (mBMMCs) were de-
veloped by culturing bone marrow cells for at least 4 weeks in
10% FBS DMEM media supplemented with IL-3 (10 ng/ml)
and KitL (25 ng/ml), as previously described [37]. Fibroblast-
like synoviocytes (FLS) were cultured from collagenase-digested
mouse ankles in 10% FBS DMEM media [38]. For co-culture
experiments where FLS are a potential source of KitL,
mBMMCs were derived as above but using only IL-3 (10 ng/
ml) [39]. Co-culture of IL-3-developed mBMMCs and FLS was
performed in the presence of 10 ng/ml recombinant IL-3, with
the cell types separated by a membrane containing 0.2 mm
pores [26]. Activation of IL-3/KitL-developed mBMMCs via
FccRIII was achieved by low-speed centrifugation against plate-
bound 2.4G2 Ab as described [35]. For these experiments, cells
were maintained in their pre-incubation medium (i.e., contain-
ing IL-33 if added, as well as any mediators released through
the action of IL-33 prior to crosslinking of FccRIII by plate-
bound 2.4G2). Quantification of cytokine array spot density for
the Mouse Cytokine Array Panel A was performed using NIH
ImageJ and normalized to positive controls in each membrane
as per manufacturer instructions.
Real-time Quantitative PCR (qPCR)
Total RNA was isolated from mBMMCs, FLS, and ankle joints
using the RNeasy minikit (Qiagen, Valencia, CA), followed by
qPCR employing primers specific for IL-6, IL-1b, TNF-a, IL-33,
CXCL2, b-Actin and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) [26,33,40].
Statistical Analysis
P values were calculated by Student’s t-test, where normality
was confirmed using the Kolmogorov-Smirnov test, by Mann-
Whitney for non-parametric data, and by ANOVA for curves
(GraphPad Prism, version 4.0). Synergistic interaction between
stimuli was evaluated using linear regression (SAS, version 9.2). P
values smaller than 0.05 were considered significant.
Results
ST2 Promotes Disease Severity and Mast Cell Activation
in K/BxN Arthritis
To explore the role of IL-33 in K/BxN arthritis and to
evaluate early immune complex-mediated activation of MCs, we
induced arthritis in mice lacking ST2 as well as in WT control
mice. In agreement with published data [31], we found that
ST2
2/2 animals exhibited less severe arthritis (Figures 1A and
1B). Correspondingly, histological measures of arthritis were
reduced, as was tissue expression of IL-6, IL-1b and TNF-
a (Figures 1C and 1D). Congruent with the prior demonstration
in arthritic day 4 tissues that MC degranulation is impaired by
ST2 deficiency [31], we found that acute MC-dependent
vascular edema (‘‘flare’’) [33] was reduced in the transgenic
mice 30 minutes after serum administration (Figure 1E). These
results confirm the importance of ST2 in this model, including
in initial MC activation.
IL-33 Amplifies FccRIII-mediated Mast Cell Mediator
Production
FccRIII and FccRII are stimulatory and inhibitory IgG
receptors, respectively, that mediate opposing effects on immune
complex-induced MC activation. In K/BxN arthritis, engraftment
experiments have shown that effective engagement of synovial
MCs requires the activating IgG receptor FccRIII [35]. Further,
synovial MCs lacking FccRIII fail to degranulate upon serum
administration [33]. Expression of the C5a complement receptor
CD88 by MCs is also required, though at a step downstream of
degranulation [33]. To assess whether IL-33 enhances MC
activation via FccRIII, we employed an established in vitro system
[35]. WT mBMMCs and transgenic mBMMCs lacking FccRII
were cultured for 4 hours in the presence or absence of IL-33. The
resulting cells were then activated via plate-bound anti-FccRII/III
Ab (clone 2.4G2). IL-33 markedly amplified IL-6 production by
FccRII
2/2 cells (Figure 2A). Interestingly, whereas activation of
Mast Cell Priming by IL-33
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of the inhibitory receptor FccRII, IL-33 enabled MC to partially
bypass this blockade and respond productively to this immune
complex mimic (Figure 2B). Of note, we failed to observe any
effect of IL-33 on exocytosis of the granule constituent b-
hexosaminidase (Figure 2C), a defect that could not be reversed
using published methods [23,31], including overnight pre-in-
cubation with IgE (anti-trinitrophenyl, 0.3 mg/ml) or K/BxN
mouse serum (1:100-1:1) (data not shown). We also could not
identify a synergistic effect of exogenous IL-33 and C5a in our
mBMMC, with or without concomitant FccRII/III ligation (data
not shown).
To understand more fully the effect of cooperative IL-33- and
FccRIII-mediated activation of MCs, we employed a multiplex
array to evaluate cytokines and chemokines elaborated by 2.4G2-
stimulated FccRII
2/2 mBMMCs, pre-incubated with IL-33 or
vehicle for 4 hours. The results confirmed our IL-6 data, and
showed that amplification extended to other mediators as well,
most prominently TNF-a and CXCL2 (Figure 2D, quantitated in
Figure 2E). The latter finding is particularly interesting, since
arthritis is neutrophil dependent and the receptor CXCR2 has
been implicated in IL-33-mediated neutrophil recruitment
[41,42,43]. Selected results were further confirmed by specific
ELISAs (Figure 2F). Whereas IL-1b has been shown to be a key
MC-derived arthritogenic cytokine [35], we assayed for IL-1b in
lysates of FccRIII-stimulated FccRII
2/2 mBMMCs and found
a marked increase after IL-33 pre-incubation (Figure 2F). Linear
regression demonstrated that the effect of sequential stimulation by
IL-33 followed by FccRIII ligation far exceeded an additive effect,
confirming synergy (TNF-a P=0.0005, IL-1b and CXCL2
P,0.0001). Interestingly, in mBMMCs stimulated with IL-33
and subsequently washed to remove released cytokine, accumu-
lation of intracellular cytokine was observed for IL-6 and IL-1b,
but not TNF-a (Figure 2G).
Figure 1. ST2 deficiency attenuates K/BxN arthritis. Arthritis was initiated in ST2
2/2 mice and their WT littermates via intraperitoneal
administration of K/BxN mouse serum on days 0 and 2 (n=5/group). (A) Clinical score on a 0–12 scale, P,0.0001, WT versus ST2
2/2. (B) Change in
ankle thickness, P,0.0001, WT versus ST2
2/2. (C) Histomorphometric quantification of arthritic tissue (5 ankles/group). (D) Cytokine mRNA in ankle
lysates (10 ankles/group from two separate experiments) at day 8 or 10 arthritis. (E) Acute change in wrist and ankle thickness (‘‘flare’’) measured 30
minutes after initial serum administration (n=5/group). Results shown are the mean 6 SEM. Panels A–C&E reflect 1 of 2 experiments with similar
results. *P,0.05, **P,0.01, WT versus ST2
2/2.
doi:10.1371/journal.pone.0047252.g001
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Rather than FccR Expression
Exploring the mechanism of the observed synergy, we examined
whether IL-33 pre-incubation altered FccR expression and/or
downstream processes involved in the expression, biosynthesis, and
release of mediators. Reciprocal modulation of FccRII and
FccRIII expression is a well-recognized pathway for enhancing
the responsiveness of cells to immune complexes [44], although we
have been unable to confirm that this mechanism is active in either
Figure 2. IL-33 enhances FccRIII-mediated cytokine production by mast cells. (A–C) FccRII
2/2 or WT B6 mBMMCs were pre-incubated with
or without IL-33 (10 ng/ml) for 4 hours, and then cells in pre-incubation media were spun onto plates pre-coated with anti-FccRII/III Ab (2.4G2).
Supernatants were harvested at 16 hours and assayed for IL-6 (A&B) and the granule mediator b-hexosaminidase (C). Differences in baseline IL-6
production were reproducibly observed between FccRII
2/2 and B6 mBMMCs, and may reflect divergent genetic backgrounds or other factors. (D)
FccRII
2/2 mBMMCs incubated with or without IL-33 for 4 hours were activated by plate-bound 2.4G2 Ab (10 mg/ml) for 16 hours and assayed by
multiplex cytokine array. (E) Quantitation of optical density of selected mediators from D (mean of 2 dots). (F) Assay of mediators identified in D-E via
specific ELISA in separate experiments employing an identical experimental design (IL-1b performed on lysates). (G) To determine whether IL-33
induced intracellular accumulation of cytokine, B6 mBMMCs were stimulated with IL-33 (10 ng/ml) for the intervals indicated, washed62 in ice-cold
PBS, and lysed in the presence of protease inhibitors. All results representative of at least 2 independent experiments. *P,0.05, **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0047252.g002
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failed to alter surface expression of FccRII or FccRIII (Figure 3A),
consistent with the lack of an effect of IL-33 on FcR-mediated MC
activation threshold (Figure 2C). Rather, pre-incubation of
mBMMCs with IL-33 induced a marked accumulation of
transcripts that encode numerous pro-inflammatory factors. Most
remarkably, the level of IL-1b transcript increased several
hundred-fold, an effect that could be observed as low as 3–
10 pg/ml of IL-33 (Figure 3B and data not shown). We interpret
these results to indicate ‘‘priming’’ of MCs by IL-33, whereby
exposure of MC to IL-33 alters the state of the cells to enable
markedly enhanced production of pro-inflammatory mediators
upon subsequent stimulation via FccRIII.
IL-33 and ST2 Mediate Mast Cell Priming by Fibroblasts
Whereas IL-33 may be elaborated by synovial fibroblasts
[21,30], we explored the possibility that this cytokine could be
pivotal for MC-fibroblast interactions. For these experiments, we
co-cultured mBMMCs and FLS in an established transwell system
that prohibited direct cell-cell contact and permitted separate
analysis of each cell type [26]. We found that FLS induced
mBMMCs to increase their levels of transcripts for IL-6 and IL-1b.
This effect was completely abrogated in ST2-deficient MCs
(Figure 4A). Whereas IL-33 is potent at low concentrations and
unstable to manipulation, we were unable to measure this cytokine
consistently in our extended co-culture supernatants (detection
limit 10–15 pg/ml). Therefore, we repeated our studies in the
presence of blocking antibodies against IL-33 [45]. Consistent with
our ST2
2/2 findings, specific IL-33 antagonism abrogated mRNA
accumulation in WT MCs (Figure 4B). These results implicate IL-
33, acting via ST2, as the key soluble mediator driving
accumulation of pro-inflammatory cytokine mRNA in MC in
our co-culture system.
Interestingly, mBMMCs induced co-cultured FLS to increase
their expression of IL-33 and IL-6 (Figure 4C). This reciprocal
effect on FLS also required MCs to express ST2 (Figure 4D),
indicating an ST2-dependent MC-FLS pro-inflammatory loop.
Whereas MCs have recently been identified as a potential source
of IL-33 [15], we assessed IL-33 mRNA from co-cultured
mBMMCs in two experiments and found it to be either low
(,0.03 vs. GAPDH) or absent (,0.0002 vs. GAPDH), indicating
that FLS are the most likely source of IL-33 in our system. Of note,
neutralizing antibodies against IL-6 and IL-1b failed to abrogate
the loop (data not shown). Therefore, the identity of the MC-
derived soluble factor(s) mediating IL-33 mRNA up-regulation in
FLS remains to be determined.
Discussion
Among their many functions, MCs are immune sentinels,
residing near epithelial surfaces, blood vessels, and near
vulnerable body cavities where they serve to provide surveil-
lance against pathogen invasion, tissue injury, and other insults
[13,46]. Upon activation, MCs can elaborate a range of
responses depending not only upon the stimulus but also upon
their particular phenotype [4]. MCs from different tissue sites
express distinct surface receptors, intracellular proteases, and
other effector molecules. These phenotypic changes are medi-
ated by the local environment, though the detailed pathways
involved are incompletely defined.
Here, we identify a new role for IL-33 and its receptor ST2 in
IgG-mediated MC activation. We previously showed that MCs
activated via FccRIII elaborate IL-1b, and that this pathway is
required for MCs to ‘‘jump start’’ IgG-mediated K/BxN murine
arthritis [35]. However, the quantity of IL-1b found to be
elaborated by cultured MCs stimulated in vitro via FccRIII was
smaller than might have been expected given the prominent in vivo
role of this cytokine. The present work helps to bridge this gap. We
now show that exposure of MCs to IL-33 dramatically increased
their production of IL-1b upon FccRIII ligation, and that this
effect could be mimicked by co-culture with primary fibroblasts
derived from mouse synovium. Further, we found that this
Figure 3. IL-33 priming of mast cells reflects accumulation of pro-inflammatory mRNA. (A) B6 mBMMCs were incubated with IL-33 (10 ng/
ml) and analyzed for surface expression of inhibitory (FccRII) and stimulatory (FccRIII) IgG receptors by flow cytometry at the indicated time points. (B)
Cytokine mRNA expression in B6 mBMMCs exposed to IL-33 (10 ng/ml) for 4 hours. Results reflect at least 2 independent experiments.
doi:10.1371/journal.pone.0047252.g003
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augmented IL-33 expression in co-cultured FLS, representing
a potential amplification loop (Figure 5). The in vivo importance of
these in vitro observations was suggested by the reduced intensity of
K/BxN arthritis in ST2
2/2 mice, a phenotype associated by
others with altered MC activation [31].
Beyond IL-1b, we found that IL-33 priming of MCs enhanced
FccRIII-mediated release of multiple other mediators, including
CXCL2. The CXCL2 receptor CXCR2 is required for the
development of full pathology in K/BxN arthritis, and in
particular for neutrophil recruitment [29,41,43,47]. Our findings
therefore develop further our understanding of mechanisms by
which MCs help recruit neutrophils to the inflamed joint [33].
These results are consistent with published data showing that
IL-33 amplifies mediator production resulting from stimulation of
MCs via IgE, since both FccRIII and FceRI signal via a common
Fc receptor c chain [24,25]. Further, our results confirm that IL-
33 can itself drive MC production of a range of mediators,
including the unusual combination of IL-6 and IL-2 that could
potentially contribute to the subversion of regulatory T cell
function (Figure 2D) [48]. Such direct stimulation of MCs may
contribute to inflammatory arthritis, particularly in chronic
synovitis, when the population of synovial MCs is often markedly
expanded [11].
However, our results suggest an alternate mechanism by which
IL-33 contributes to acute MC activation in IgG-mediated
arthritis. In K/BxN arthritis, the MC-dependent ‘‘flare’’ begins
within minutes of serum administration, a timeframe probably too
short for de novo IL-33 synthesis. Rather, consistent with published
results demonstrating the key role of FccRIII in synovial MC
activation [33,35], our data suggest that constitutive signals
mediated via IL-33 promote immune complex responsiveness of
synovial MCs, defining therefore a new model for a permissive role
of IL-33 in MC-dependent immune complex disease (Figure 5).
Whereas IL-33 pre-incubation induces accumulation of mRNA
(and to a lesser extent intracellular protein) for key pro-
inflammatory cytokines whose production by subsequent FccRIII
ligation is markedly enhanced, we hypothesize that such ‘‘pre-
loading’’ of MC by IL-33 represents an important component of
the priming mechanism, though other factors may also be
involved.
Our results also expand appreciation of the integral relationship
between MCs and fibroblasts. We previously demonstrated
a profound effect of fibroblasts on the development of MCs
[5,6,26]. The current work builds upon these studies, showing that
IL-33 is a key mediator by which fibroblasts prime MCs for
activation by IgG immune complexes. Given the known anatomic
and functional associations of synovial MC with fibroblasts, these
cells represent the most likely source of IL-33 in the joint,
a possibility modeled by our in vitro co-culture system. However,
endothelial cells or other IL-33-producing lineages, including MCs
themselves, could potentially fulfill the same role.
While our in vitro findings correspond well to the expected
activity of MCs in arthritis, it is possible that our system fails to
model all aspects of the in vivo biology. In particular, we observed
evidence for reduced MC activation in ST2
2/2 animals exposed
to K/BxN IgG, manifested as reduced flare magnitude. This result
supports the observation that MC degranulation (observed at day
4 tissue harvest) is impaired in ST2
2/2 mice administered K/BxN
serum [31]. However, consistent with most published reports, we
found no in vitro effect of IL-33 on degranulation of cultured MCs,
either alone or together with FccRIII ligation [13,25]. Further,
whereas exposure of WT MCs to IL-33 enabled these cells to
bypass inhibition by FccRII with respect to production of IL-6, we
could not induce FccRIII-mediated degranulation or IL-1b
production (data not shown). These observations may reflect
phenotypic variance between cultured MCs and those that have
matured within synovial tissues, or potentially the absence of
Figure 4. IL-33 mediates a MC-FLS amplification loop. MCs were cultured with or without FLS for 1–2 weeks in the upper and lower chambers,
respectively, of a transwell apparatus. (A) Cytokine mRNA expression in WT and ST2
2/2 MCs after co-culture with FLS. (B) Cytokine mRNA levels in
MCs with or without anti-IL-33 Ab treatment (10 mg/ml q4d). Data represent 2 independent experiments with similar results. (C–D) Cytokine mRNA
levels in FLS. n=2 wells per condition, reflective of 2–5 pooled experiments. *P,0.05, **P,0.01, N.S., not significant.
doi:10.1371/journal.pone.0047252.g004
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in the receptor for IL-4 fail to demonstrate tissue MC de-
granulation induced by repeated injections of recombinant IL-33
[49]. Alternately, it may be that the initial MC activation step that
provides the ‘‘jump start’’ to arthritis does not obligatorily involve
degranulation. Indeed, the precise mechanisms mediating the flare
remain to be defined, and are known to involve neutrophils as well
as MCs, such that the flare is unlikely to simply represent local
anaphylaxis-like release of MC granule contents [32,50].
Our results do not define the pathways by which fibroblasts
produce and release IL-33. Indeed, this remains an area of
substantial uncertainty within IL-33 biology [34]. Like most other
members of the IL-1 family, IL-33 does not possess a signal
peptide permitting conventional secretion. Since IL-33 is inacti-
vated by caspases, it has been suggested that it may represent
a ‘‘alarmin,’’ liberated during necrosis but not apoptosis [51].
Indeed, some degree of necrosis was detectable in our cultures by
lactate dehydrogenase release (data not shown), though whether
such necrosis is relevant to our in vitro observation, or indeed to the
in vivo arthritis phenotype, is unknown. Interestingly, we recently
showed that cardiac fibroblasts can release IL-33 upon mechanical
stretch, providing one potential mechanism by which fibroblasts
within a moving joint might release IL-33, thereby priming MCs
[52]. However, this mechanism would not have been expected to
be operative in our static culture system.
In summary, our results show that IL-33 has the previously
unrecognized potential to enhance MC responses to FccRIII
ligation. Our previous studies have demonstrated that MCs
activated via FccRIII can ‘‘jump start’’ synovial inflammation, at
least in part via the pro-inflammatory cytokine IL-1b [35]. Recent
in vivo studies, confirmed here, have implicated MC expression of
ST2 in arthritis [21,31]. Our current results link these observations
together, showing that priming of MCs via IL-33 potentiates their
activation via FccRIII, resulting in markedly enhanced production
of IL-1b, IL-6, and other mediators (Figure 5). Since immune
complexes deposited within synovial tissue are a hallmark of
rheumatoid arthritis [53], our results suggest that blockade of the
IL-33/ST2 axis could benefit from a multiplier effect, dampening
cell activation resulting not only from IL-33 itself but also from
mechanisms amplified by this cytokine, including Fc receptors
ligation in MCs. These results therefore further support IL-33 as
a potential candidate for therapeutic inhibition in arthritis.
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